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Title: Monitoring of outpatient parenteral antimicrobial therapy (OPAT) and implementation of
clinical pharmacy services at a community hospital infusion unit
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Abstract
Background:
In 2004, the Infectious Diseases Society of America (IDSA) published monitoring guidelines for
outpatient parenteral antimicrobial therapy (OPAT), but no assessment of their utilization has
been reported. We evaluated adherence to these recommendations by physicians at infusion
centers and then piloted a program of supervision of monitoring by pharmacists.

Methods:
Phase I: We performed a retrospective case-control study of patients who received OPAT over
one year at two hospital infusion centers. Controls were patients treated by an infectious diseases
(ID) physician, and cases were those without an ID physician. Patients were excluded if they
received fewer than 3 days of OPAT. Clinical pharmacy monitoring services were then
implemented for patients on OPAT prescribed by non-ID physicians at one hospital’s infusion
unit. Two outcomes were measured: adherence to guidelines on monitoring, and attainment of
goal vancomycin and aminoglycoside serum concentrations when appropriate. The results for
non-ID physicians were compared to both ID physicians and subsequently a pharmacist.

Results:
Ninety nine patients were included in the retrospective study. Compared with patients who had
ID physician supervision, the non-ID physicians who prescribed OPAT for 39 patients had lower
adherence to monitoring recommendations (35.9% vs.68.3%, p=0.003). No difference could be
detected in achievement of goal vancomycin and aminoglycoside serum concentrations for the
14 cases and 19 controls requiring therapeutic drug monitoring (57.1% vs. 68.4% respectively,
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p=0.765). Seven patients were enrolled in the study after pharmacy monitoring was
implemented. Adherence to monitoring recommendations for these patients was significantly
improved compared to the prior patients that lacked ID physician supervision (35.9% vs. 100%,
p=0.0065).

Conclusions:
Non-ID physicians are less likely to monitor OPAT according to the IDSA guidelines than ID
physicians; however, pharmacist oversight improves adherence to recommendations. Further
studies of monitoring of OPAT by pharmacists should investigate the impact of pharmacist
involvement on prevention of adverse events and hospital readmissions.

Key words:
OPAT, antibiotic, monitoring, outpatient, pharmacist
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Background
Patients with moderate to severe infections may require intravenous (IV) antibiotics for their
entire course of therapy. However, many of these patients may be stable enough to receive
treatment as an outpatient. Outpatient parenteral antimicrobial therapy (OPAT) is defined as
providing IV, intramuscular or subcutaneous administration of antibiotics, antifungals, and
antivirals to patients on separate days outside of a hospital setting.1 One of the goals of OPAT is
to deliver high-quality health care while optimizing resource use and reducing costs without
compromising clinical outcomes. With the availability of antimicrobials with long half-lives that
allow for once or twice daily dosing, OPAT is feasible for a variety of infectious diseases.
Examples of infections that have been effectively treated with OPAT include skin and soft tissue
infections, osteomyelitis, bacteremia, endocarditis, and complicated urinary tract infections.2-6

Mounting evidence supports the use of OPAT. The documented benefits include cost savings and
patient convenience.1,2 Using OPAT allows for additional inpatient hospital beds and healthcare
resources to be available for other more acute patients and it can lead to a reduction in the risk of
healthcare-related infections.3,8 Infection acquired during a hospitalization results in an estimated
cost of $2,100 and a total cumulative cost of greater than $2 billion annually.8 An article by
Nguyen showed that the implementation of an OPAT service for a hospitalist service at his 619bed acute-care medical center translated to an estimated mean savings of over $7,000 per
patient.3 In addition to cost avoidance, OPAT can allow patients to return home, improving their
quality of life and satisfaction with care.1 Due to the cost savings and other benefits noted, OPAT
services are becoming more attractive to healthcare systems, especially in light of increasing
financial and regulatory pressures.3
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OPAT can be provided in various settings, including physician’s offices, infusion centers, longterm care facilities, dialysis centers and even the patient’s home with visiting nurse or selfadministration of the drug. In one recent U.S. study, 65% of inpatients discharged on OPAT
received infusions at home, 15% at long term care facilities, 11% at infusion centers and 9% at
other facilities such as dialysis clinics or physicians’ offices.7 The patient’s condition and source
of payment often direct where patients on OPAT may be discharged.

Several key features make an OPAT program successful and efficient (e.g. the OPAT bundle
concept as suggested by Muldoon et al.9). These include: careful patient selection; an organized
OPAT team consisting of an ID physician, infusion pharmacist, nurses, case management, billing
staff, social worker and primary care or referring physicians available to participate in care;
effective communication between the OPAT team, patient and other healthcare professionals;
optimal patient surveillance and monitoring; and a program in place to monitor outcomes.4,7,9
The American Society of Health-System Pharmacists has published guidelines highlighting the
pharmacist’s contribution to this team approach, including monitoring antimicrobial therapy .10,11

Unlike the inpatient setting where a patient is closely observed, patients on OPAT may
experience much less monitoring.1 At least 25% of patients receiving OPAT will develop
adverse reactions however, and up to 10% of patients on OPAT will discontinue therapy due to
an adverse event.1,4 A 1999 report of 269 patients who received OPAT at home during a 2 year
period, found that 16% developed leukopenia, 7% neutropenia, 4% thrombocytopenia and 8%
nephrotoxicity. Overall, 8% of patients required re-hospitalization. The authors concluded that
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monitoring of patients receiving OPAT is important to prevent complications and hospital
readmissions.12

In 2004 the Infectious Diseases Society of America (IDSA) updated their 1997 guidelines for
OPAT, including recommendations for monitoring. These practice guidelines serve as a
benchmark for clinical monitoring and quality assurance.1,4 With the implementation of these
guidelines plus vigilant risk assessment and management, the hazards associated with OPAT can
be minimized.1 The guidelines are voluntary and no reports of rates of adherence have been
published. Therefore, we evaluated adherence to the laboratory monitoring recommendations,
including attainment of goal serum drug concentrations, by physicians at infusion centers and
then pilot clinical pharmacy monitoring services in an existing OPAT program.

Methods
Phase 1
This was a two phase study approved by the local institutional review board. The first phase was
a retrospective case-control study. Controls were defined as patients treated by an ID physician,
and cases were defined as those patients without the supervision of an ID physician. Patients who
received OPAT from 11/2011 to 10/2012 at the infusion centers of two community teaching
hospitals in Springfield, Illinois were retrieved from the hospitals’ electronic pharmacy
databases. Cases were differentiated from controls by identifying the physician prescribing
antimicrobials as either an ID specialist or not. Patients were excluded if they received fewer
than 3 days of OPAT. We collected the following data for the cases and controls by reviewing
individual medical records: patient demographics, infection treated, antibiotics administered,
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physician specialty, microbiology results and monitoring. The monitoring included frequency of
laboratory testing, as well as serum concentration values for vancomycin and aminoglycosides.
Two primary outcomes were assessed: adherence to monitoring of OPAT based on guidelines,
and in patients prescribed vancomycin or an aminoglycoside, attainment of therapeutic serum
drug concentrations. In order to be counted as adherent to monitoring, all laboratory parameters
would have to be ordered as recommended in table 1. Physicians were considered non-adherent
to monitoring if any laboratory parameter was omitted during each week of therapy. The goals
for serum concentrations were assessed according to local hospital guidelines (Appendix A)
based on literature and national standards.13-19

Phase 2
Based on the results of the first phase, we determined a greater need for monitoring of patients
who did not have ID physician supervision. We hypothesized that the integration of a pharmacist
would help improve adherence to monitoring recommendations in this patient population.
Therefore, the second phase of the study involved implementation of pharmacy monitoring
services for patients receiving OPAT without ID physician supervision from 11/2012 to 4/2013
at one of the infusion centers.

We chose to pilot pharmacy monitoring services of OPAT at that hospital’s infusion unit because
of the presence of an infectious diseases pharmacy resident to assist with the program. This
infusion center is a 24-hour ten bed facility where patients can receive blood transfusions or
parenteral drug therapy including chemotherapy and antibiotics. The infusion center clerk sent a
list of patients scheduled to receive that day’s medication infusions to the hospital’s central
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pharmacy each morning. The inpatient pharmacy prepared the patients’ parenteral products as
usual while an investigator reviewed this list for adults receiving antimicrobials prescribed by
non-ID physicians. When eligible patients were identified, the prescribing physician was called
to obtain approval for ordering laboratory monitoring and adjusting doses based on results. To
create awareness of the program, hospitalist groups and case managers were educated on the
potential service during staff meetings. Adherence to monitoring recommendations for
outpatients under the care of a pharmacist was compared with that of historic controls, patients
who lacked ID physician supervision before pharmacy monitoring was implemented.

Analysis with Chi-square test was used to compare the categorical variables of adherence to
monitoring recommendations and attainment of goal serum drug concentration. All tests were 2tailed and p<0.05 was considered statistically significant.

Results
Phase 1: Ninety nine patients receiving OPAT at the hospital infusion centers from 11/2011 to
10/2012 were included. Of these, 39 lacked ID physician supervision. A majority of the patients
that received OPAT were female (n=63, 64%) and the mean age was 63.1 years (SD 16.6).
Baseline demographics between cases and controls were similar. A wide variety of clinical
indications and microorganisms were documented (table 2). Urinary tract infections and acute
skin or soft tissue infections were the most common diagnoses. Causative organisms were
identified in 59 patients receiving OPAT. The most common pathogens were Staphylococcus
aureus (20.2%) and Escherichia coli (15.1%). Table 3 lists the antimicrobials prescribed. All
were administered intravenously. As expected, antimicrobials that can be administered once or
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twice daily were most commonly prescribed. Vancomycin, 3rd and 4th generation cephalosporins,
ertapenem and daptomycin were the most frequently used parenteral antimicrobials. The median
duration of aminoglycoside therapy prescribed by both ID and non-ID physicians was 6 days.
For vancomycin, the median duration of therapy prescribed by ID physicians was 14 days, and
by non-ID physicians was 7 days.

Patients without ID physician supervision had lower adherence to monitoring recommendations
(35.9% vs. 68.3%; OR 3.9, 95% CI 1.6-9; p=0.003). The cases also had numerically lower
attainment of goal vancomycin and aminoglycoside serum concentrations although this was not
statistically significant (57.1% vs. 68.4%; OR 1.6, 95% CI 0.4-6.8; p=0.765). Table 4 lists the
monitoring parameters that physicians (ID and non-ID) omitted. A majority of patients, whose
physicians did not adhere to guidelines, received no additional laboratory monitoring after their
hospital discharge.

Phase 2: We piloted pharmacy monitoring services for seven patients, who received OPAT
prescribed by non-ID physicians, at one of our infusion centers. These patients received OPAT
for either urinary tract infection (n=4), chronic sinusitis (n=2) or osteomyelitis (n=1).
Antibacterials administered include ceftriaxone (n=2), cefepime (n=2), and ceftazidime,
vancomycin and gentamicin (1 each). All prescribers accepted the pharmacist’s offer to monitor
these patients. Adherence to monitoring recommendations for these patients was significantly
improved compared to the patients that lacked ID physician supervision prior to pharmacy
monitoring services being implemented (35.9% vs. 100% , p=0.0065).
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Discussion
To our knowledge, no reports on the consistency of OPAT monitoring have been published for
physicians or pharmacists. We therefore assessed adherence to the laboratory monitoring
recommendations in the IDSA guidelines for OPAT, and attainment of goal serum drug
concentrations at two infusion centers.
As suspected, the evaluation revealed that patients with ID physician supervision had
significantly better adherence to monitoring recommendations. These patients had a higher
attainment of goal serum concentrations of vancomycin and aminoglycosides as well; although,
this was not statistically significant. Based on these results, there is room for improvement in
both groups however with only 55.5% of the patients overall receiving monitoring consistent
with national guidelines.

In the second phase of the study, we implemented pharmacy monitoring services at one of our
infusion centers and achieved 100% adherence to monitoring guidelines for patients on OPAT
prescribed by non-ID physicians. It was decided to pilot these pharmacy monitoring services on
OPAT prescribed by non-ID physicians because of lower initial adherence to monitoring
guidelines in this group. We hypothesized that these physicians would be most amenable to
assistance with monitoring and adjusting doses for antimicrobials. After implementation of the
clinical pharmacy services, attainment of goal serum drug concentrations was not compared
since only two patients required this service. Only seven patients were enrolled in the second
phase of the study because our study time frame was six months and the majority of OPAT at our
institution was prescribed by ID physicians. It would have been ideal to include more patients
over a longer time frame, but we felt this wouldn’t have changed the results. Patients that had
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pharmacist monitoring oversight were significantly more likely to be monitored according to
guideline recommendations after 6 months, and the pharmacists involved in preparation of the
parenteral antimicrobials felt the process was simple enough that a sharp decline in adherence
would be unlikely. The data was brought to the pharmacy and therapeutics committee and it was
agreed that the practice should continue after the pharmacy resident coordinating the project left
the medical center. This study showed that a pharmacist can follow guideline recommendations
for monitoring OPAT and this finding is important because not all hospitals have access to ID
physicians or require that a specialist see the patient prior to discharge on OPAT. Most infusion
centers, however, do have pharmacists prepare the parenteral antimicrobials for outpatient
administration; therefore, this monitoring strategy could be implemented virtually anywhere.
The pilot program described here allowed us to test our processes and bring forth a
recommendation that the monitoring service be continued.

Our study had several limitations, however. First, we did not have access to laboratory results
performed at outlying facilities. This could underestimate adherence to monitoring
recommendations, but it was not expected to occur often enough to impact the results. Second,
our sample size was limited because we were targeting only patients receiving antimicrobials at
two infusion centers located in Springfield, Illinois, and not all locations where OPAT could be
administered. However, we feel that the results of this study are applicable to all sites that
provide OPAT because monitoring antibiotics is fundamental to optimizing patient care and
preventing unnecessary adverse drug events. Third, for phase I of the study we included patients
from two infusion centers with different hours of operation (one infusion center was operational
for 24 hours; whereas, the other was open only from 8am-5pm). This could impact the type of
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parenteral antimicrobial therapy received at each location. Data from two institutions had to be
combined because OPAT has not been a common practice without ID physician supervision
locally. Lastly, we did not participate in the diagnosis or treatment decisions for the infection,
nor did we ascertain whether alternative parenteral or oral therapy would be more appropriate as
other studies have evaluated.7 This data would have been helpful in providing proper
antimicrobial stewardship.

With many hospitals facing increasing economic pressures, limited space for patient care, and
healthcare reform mandating efficient, evidence-based care, OPAT is an attractive option that
will likely increase in popularity. With OPAT services available, stable patients can be
discharged safely, leading to bed turnover and cost savings.3,10 It would be prudent to monitor
these patients closely to prevent unnecessary adverse events and possible readmissions. IDSA
proposed recommendations for monitoring patients on OPAT almost a decade ago, but little
research in this area exists.4 Additionally, Muldoon et al suggests an OPAT bundle to enhance
efficiency and optimize patient care.9 As part of this bundle, clinical pharmacists can play a vital
role to improve patient care by not only supervising drug preparation, but by assessing safety and
efficacy of pharmacotherapy through monitoring pertinent laboratory parameters, then adjusting
and optimizing doses of antimicrobials under the supervision of a physician familiar with OPAT.

A study by Heintz and colleagues looked at the impact of a multidisciplinary team review of
OPAT prior to discharge. This team consisted of an ID physician, ID pharmacist and a case
manager. The case manager would consult the pharmacist for further assessment of a patient
being discharged on OPAT. The ID pharmacist, under the supervision of the ID physician, made
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a variety of interventions focusing on safety, efficacy and simplification of complex regimens. In
one year, these interventions led to 228 hospital days being avoided and approximately $366,000
in hospital bed cost savings.7 Although, this would be an excellent model to follow, it is not
feasible at all hospitals. As our results indicated, the routine monitoring of patients on OPAT
after discharge is limited. Our study also showed the impact a pharmacist can have on adherence
to laboratory monitoring recommendations after a patient is discharged on OPAT. This
improvement in adherence could correlate to improved outcomes such as fewer adverse events
and hospital readmissions. With pharmacist oversight, dosing of antimicrobials can be better
optimized as previously documented.7 Adverse reactions could also be prevented and managed
earlier. For example, nephrotoxicity from aminoglycosides or vancomycin can be prevented
through vigilant monitoring and prescribing physicians can be alerted to any abnormal laboratory
results before significant harm occurs in the patient. Therefore, pharmacists can have a
significant role to play as part of OPAT to optimize patient care. This study serves as a
benchmark for pharmacists, as drug therapy experts, to work in tandem with prescribers to
manage patients on OPAT.

Conclusion:
Infectious diseases physicians are more likely to monitor patients receiving OPAT at infusion
centers according to guidelines compared to non-ID prescribers. Attainment of goal serum drug
concentrations was also higher in these patients, but this was not statistically significant in our
sample. There is an opportunity for improvement in both groups, and implementing pharmacist
oversight can improve adherence to laboratory monitoring recommendations for patients that do
not have ID physician supervision. Future studies should evaluate whether pharmacists can
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improve care for all OPAT patients and confirm if achievement of guideline recommendations
provides better patient outcomes.
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Table 1: Recommendations for laboratory monitoring of OPAT4,20,21
Antimicrobial
agent

CBCa
(no. of
times/week)

Aminoglycosides
(gentamicin,
tobramycin,
amikacin)
Beta-lactams
(penicillins,
cephalosporins,
aztreonam,
carbapenems)
Antipseudomonal
penicillins
Clindamycin
Daptomycin
Fluoroquinolones
Linezolid
Pentamidine

Potassium
level (no. of
times/week)

Once

Renal function
tests b
(no. of
times/week)
Twice

-

Liver
enzyme tests
(no. of
times/week)
-

Once

Once

-

-c

Once

Once

Once

-

Once
Once
Once
Twice

Once
Once
Twice

Twice

Twice

-

-

-

Once

Once

Once

Once

-

Once
Once

Once

Once

Once
-

Once

Once

-

-

Troughs as clinically indicated (if at
steady state, can obtain q5-7 days)

Once

Twice

Twice

Once

Magnesium levels once per week

Once
-

Once
-

-

Once
Once

Once
Once

Once
Once

Once

Once

Foscarnet

Once

Twice

Twice

Once

Ganciclovir

Twice

Once

-

-

Quinupristindalfopristin
Telavancind
Tigecyclined
Trimethoprimsulfamethoxazole
Vancomycin
Antifungals
Amphotericin B,
including lipid
formulations
Azole antifungals
Echinocandins
(micafungin,
caspofungin,
anidulafungin)
Antivirals
Acyclovir
Cidofovir

a.
b.
c.
d.

Once
Once
Once

Others

-Troughs as clinically indicated (if at
steady state, can obtain q5-7 days)
-Clinical monitoring for vestibular
and hearing dysfunction at each visit

CPK at least weekly

Blood glucose level daily; chemistry
profile twice per week
Monitor for arthralgias
Prior to use, women of childbearing
potential should have a serum
pregnancy test

Magnesium levels once per week
Urinalysis and chemistry profile
once per week
Chemistry profile with calcium and
magnesium levels once per week

CBC = Complete Blood Count, including platelets and a differential count of leukocytes
Renal function tests may include serum creatinine, blood urea nitrogen levels or urinalysis
Weekly liver enzyme tests with oxacillin, nafcillin and carbapenems
Telavancin and tigecycline monitoring was based on FDA-approved prescribing information
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Table 2: Clinical and Microbiologic Indications for OPAT by Prescriber
Non-ID Physician Patients, N=39
Infection
n (%)
UTI
21 (46.7)
SSTI
9 (20.0)
Bacteremia
6 (13.3)
HCAP
4 (8.9)
CAP
3 (6.7)
Osteomyelitis
1 (2.2)
Chronic sinusitis
1 (2.2)

Microbiology
results
Culture negative
Escherichia coli
Pseudomonas
aeruginosa
Klebsiella pneumoniae
MRSA

n (%)
14 (29.8)
9 (19.1)
6 (12.8)
5 (10.6)
4 (8.5)

ID Physician Patients, N=60
Infection
n (%)
SSTI
20 (32.8)
UTI
12 (19.7)
Bacteremia
8 (13.1)
IAI
6 (9.8)
Osteomyelitis or PJI
5 (8.2)
Endocarditis
2 (3.3)
HCAP
2 (3.3)
PJI
2 (3.3)
Chronic sinusitis
2 (3.3)
Meningitis
1 (1.6)
Syphilis
1 (1.6)
Microbiology
results
Culture negative
MRSA

n (%)
26 (36.6)
10 (14.1)

Escherichia coli
6 (8.5)
MSSA
5 (7.0)
Anaerobes*
5 (7.0)
Coagulase negative
Enterobacter cloacae
2 (4.3)
Staphylococcus spp.
3 (4.2)
Viridans Streptococcus
1 (2.1)
Viridans Streptococcus
3 (4.2)
Streptococcus
Microaerophilic
pneumoniae
1 (2.1)
Streptococcus
2 (2.8)
Serratia marcescens
1 (2.1)
Proteus mirabilis
2 (2.8)
MSSA
1 (2.1)
Pseudomonas aeruginosa
2 (2.8)
Morganella morganii
1 (2.1)
Streptococcus pneumoniae
1 (1.4)
Klebsiella oxytoca
1 (2.1)
Citrobacter koseri
1 (1.4)
Group B Streptococcus
1 (2.1)
Morganella morganii
1 (1.4)
Aerococcus urinae
1 (1.4)
Citrobacter freundii
1 (1.4)
Enterococcus faecalis
1 (1.4)
Klebsiella pneumoniae
1 (1.4)
Note: Values add up to greater than 100% because some patients had more than one infection
Key: MRSA: methicillin resistant Staphylococcus aureus; MSSA: methicillin susceptible
Staphylococcus aureus; SSTI: skin or tissue infections; UTI: urinary tract infections; HCAP:
health-care associated pneumonia; CAP: community acquired pneumonia; IAI: intra-abdominal
infections; PJI: prosthetic joint infections; *Anaerobes: Peptostreptococcus spp. (n=2),
Bacteroides fragilis (n=1), Clostridium spp.,non-difficile (n=1), Prevotella spp. (n=1)
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Table 3: Antibacterials administered based on physician supervision
Non-ID physician
Drug
n (%)
Ceftriaxone
11 (25.6)
Cefepime
8 (18.6)
Gentamicin
7 (16.3)
Ertapenem
5 (11.6)
Vancomycin
5 (11.6)
Tobramycin
2 (4.7)
Daptomycin
2 (4.7)
Linezolid
1 (2.3)
Azithromycin
1 (2.3)
Meropenem
1 (2.3)

ID physician
Drug
n (%)
Vancomycin
13 (19.7)
Daptomycin
12 (18.2)
Ertapenem
11 (16.7)
Ceftriaxone
8 (12.1)
Cefepime
7 (10.6)
Gentamicin
7 (10.6)
Tobramycin
3 (4.5)
Benzathine Penicillin G
1 (1.5)
Ceftazidime
1 (1.5)
Tigecycline
1 (1.5)
Linezolid
1 (1.5)
Azithromycin
1 (1.5)
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Table 4: Weekly laboratory parameters not ordered as recommended by guidelines
Non ID physicians
Antimicrobial
agent (N)
Ceftriaxone (11)
Gentamicin (7)
Tobramycin (2)
Ertapenem (5)
Cefepime (8)
Daptomycin (2)
Vancomycin (5)
Meropenem (1)

Complete blood
count (n)
5 (45%)
6 (86%)
1 (50%)
1 (20%)
4 (50%)
2 (40%)
1 (100%)

Renal function
tests (n)
5 (45%)
4 (57%)
1 (50%)
1 (20%)
4 (50%)
1 (20%)
1 (100%)

Liver enzyme
tests (n)
7 (64%)
2 (40%)
1 (100%)

ID physicians
Antimicrobial
agent (N)
Ceftriaxone (8)
Tobramycin (3)
Ertapenem (11)
Daptomycin (12)
Vancomycin (13)

Complete blood
count (n)
4 (50%)
1 (33%)
3 (25%)
5 (38%)

Renal function
tests (n)
4 (50%)
1 (33%)
3 (25%)
5 (38%)

Liver enzyme
tests (n)
4 (50%)
2 (18%)
3 (25%)
-

CPK (n)
2 (100%)
-

CPK (n)
6 (50%)
-
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Appendix A: Goals for Serum Drug Concentrations
1. Vancomycin13,14
a. Severe infections (e.g. meningitis, pneumonia, endocarditis, bacteremia, severe soft
tissue infection or osteomyelitis): trough between 15-20 mcg/mL
b. Mild to moderate skin and soft tissue or urinary tract infection (after ruling out
systemic disease): trough between 10-15 mcg/mL
2. Aminoglycosides – conventional dosing15,16
a. Peak:
i. Severe infections (e.g. bacteremia, neutropenic fever, pneumonia):
a. Gentamicin and tobramycin: 8-12 mcg/mL
b. Amikacin: 25-40 mcg/mL
ii. Mild to moderate infections (e.g. pyelonephritis, urinary tract infections):
a. Gentamicin and tobramycin: 5-8 mcg/mL
b. Amikacin: 15-25 mcg/mL
iii. Synergy (gentamicin only) for gram positive organisms: 3-5 mcg/mL
b. Trough (gentamicin and tobramycin):
i. Severe infections:
a. Gentamicin and tobramycin: <2mcg/mL
b. Amikacin: <10mcg/mL
ii. Mild to moderate infections and synergy (gentamicin only) for gram positive
organisms:
a. Gentamicin and tobramycin: <1mcg/mL
b. Amikacin: <10mcg/mL
3. Aminoglycosides – once-daily dosing16-19
a. Trough (gentamicin, tobramycin and amikacin): <1mcg/mL
b. 16-18 hours post-infusion serum aminoglycoside concentration:17,18
i.
Gentamicin and tobramycin: < 2 mcg/mL
ii.
Amikacin: 2.5 – 5 mcg/mL
c. 6-14 hours post-infusion serum aminoglycoside concentration
i.
Follow nomogram, as suggested by Nicolau et al19

